PDTs, biosimilars hot topics at AMCP meeting | AMCP 2023
The Academy of Managed Care Pharmacy is throwing its support behind federal legislation that would create a Medicare benefit category for prescription digital therapeutics.
The Silver Linings of the Pandemic Playbook: Telehealth, 'Whole-Person Health,' per Rodrigo Cerdá, M.D., M.P.H., of Independence Blue Cross
The senior vice president of health services and chief medical officer at Independence Blue Cross in Philadelphia discusses the spotlight that the COVID-19 pandemic put on behavioral health and Independence's integration of behavioral health into its coverage and care management in this month's episode of “What's on Your Mind?" podcast.
Idaho bill would criminalize giving an mRNA vaccine: ‘It feels like an attack on our profession’
Although it’s not likely to pass, at least not this year, opponents say the proposal is already accelerating the spread of false claims and sowing distrust of physicians.
What Reimbursable Remote Care Through New CMS CPT Codes Means For Patients
Briana Contreras, an editor of Managed Healthcare Executive, chats with Bronwyn Spira, CEO and founder of Force Therapeutics, in this week's episode about CMS' new CPT codes that were introduced in 2022.
FDA Updates for the Week of March 20, 2023
FDA approvals this week include: novel treatment for invasive candidiasis, an accelerated approval to Zynyz for Merkel cell carcinoma, the high-concentration Humira biosimilar Hyrimoz, and extension of Evkeeza’s indication to include young children. The agency also issued two complete responses this week: for Incyte’s extended-release Jakafi and for AbbVie’s Parkinson’s therapy.
Tis Full and Very, Very Expensive: the 2023 Specialty Drug Pipeline | AMCP 2023
Specialty drugs are expected to comprise 80% of the FDA approvals this year. Among them are gene therapies for hemophilia A and Duchenne muscular dystrophy priced at between $2 million and $3 million.
2 Clarke Drive Cranbury, NJ 08512